Outsourcing Pharma

FEBRUARY 15, 2024

Artax Biopharma, a clinical-stage biotech company focused on transforming the treatment of autoimmune diseases, has dosed the first patient in its phase 2a trial evaluating oral, small molecule, AX-158 for the treatment of psoriasis.

80

80

Outsourcing Pharma

SEPTEMBER 14, 2023

company Rome Therapeutics plans to use the proceeds of its $72 million Series B round to take an experimental autoimmune disease treatment through early clinical testing.

99

99

Outsourcing Pharma

FEBRUARY 15, 2024

Artax Biopharma, a clinical-stage biotech company focused on transforming the treatment of autoimmune diseases, has dosed the first patient in its phase 2a trial evaluating oral, small molecule, AX-158 for the treatment of psoriasis.

59

59

European Pharmaceutical Review

JUNE 23, 2023

Study data from a major trial has demonstrated RNA CAR-T (rCAR-T) therapy Descartes-08 facilitated significant and long-lasting clinical improvement in generalised myasthenia gravis (gMG). This is the first clinical trial using rCAR-T to treat autoimmunity.

Chemotherapy 98

Chemotherapy 98

European Pharmaceutical Review

NOVEMBER 9, 2023

Following her presentation on age-related disease at BioFuture 2023, Executive Vice President of Drug Development for MyMD Pharmaceuticals ® , Jenna Brager, shares with EPR why the company’s next-generation tumour necrosis factor (TNF)-alpha inhibitor has potential in inflammatory and autoimmune disorders.

Pharmaceutical Companies 109

Pharmaceutical Companies Pharmaceutical Companies Immunization Process Improvement 109

European Pharmaceutical Review

OCTOBER 14, 2022

Telitacicept is a proprietary novel fusion protein from RemeGen to treat autoimmune diseases. MG is a chronic autoimmune neuromuscular disease that causes patients to be prone to fluctuating muscle weakness. It can affect eye movements, swallowing, speech and respiratory functions; it can even be life-threatening in severe cases.

FDA 116

FDA Immunization 116

STAT

NOVEMBER 28, 2023

Belgium drugmaker Argenx said Tuesday that its antibody medicine failed to achieve the goals of a late-stage study for a platelet-destroying autoimmune disorder — a setback in the company’s efforts to expand the drug’s use. Argenx shares were down 12% in early trading.

Immunization 104

Immunization 104

BioPharm

JANUARY 4, 2024

AstraZeneca’s acquisition of Gracell includes a clinical-stage autologous cell therapy targeting hematologic malignancies and autoimmune diseases and a proprietary manufacturing platform.

52

52

European Pharmaceutical Review

APRIL 26, 2024

It is approved for autoimmune disorders within disease areas such as gastroenterology and dermatology. Recent biosimilar developments In February 2024, the EMA’s Committee for Medicinal Products for Human Use (CHMP) granted a positive opinion for Pyzchiva as a biosimilar to treat the autoimmune condition plaque psoriasis.

Packaging 52

Packaging Pharmaceutical Companies Pharmaceutical Companies FDA 52

Pharmaceutical Technology

DECEMBER 21, 2023

Sudo plans to advance two TYK2 candidates into clinical testing next year for the treatment of autoimmune and neurologic conditions.

52

52

STAT

JULY 16, 2023

Belgian drugmaker Argenx said Monday that its antibody treatment called Vyvgart significantly delayed the progression of an autoimmune nerve disorder that causes people to lose feeling and muscle strength in the arms and legs.

FDA 95

FDA 95

pharmaphorum

SEPTEMBER 16, 2022

Now, Verily has announced that early results from its “next generation immune mapping technology” Immune Profiler platform have already identified “more effective therapeutic options against G protein-coupled receptors (GPCR) in autoimmune and other immune-mediated diseases”. It also bodes well for improving clinical trial success rates.

Immunization 135

Immunization FDA 135

European Pharmaceutical Review

JANUARY 2, 2024

billion, AstraZeneca has agreed to acquire Gracell Biotechnologies, supporting the development of cell therapies in haematology and autoimmune diseases. The novel treatment is being studied in multiple haematologic malignancies and autoimmune diseases. For an upfront price of $1.0

Immunization 85

Immunization 85

European Pharmaceutical Review

DECEMBER 14, 2022

a wholly-owned subsidiary of Nimbus Therapeutics and Nimbus Therapeutics’ tyrosine kinase 2 (TYK2) inhibitor NDI-034858, an oral, potential best-in-class selective allosteric TYK2 inhibitor for multiple autoimmune diseases following successful recent Phase IIb results in psoriasis. For $4 billion , Takeda will acquire Nimbus Lakshmi, Inc.,

87

87

Pharmaceutical Technology

FEBRUARY 8, 2024

Undisclosed 1 is under clinical development by Palleon Pharmaceuticals and currently in Phase I for Autoimmune Disorders.

40

40

pharmaphorum

AUGUST 5, 2022

MiroBio was formed in 2019 to develop checkpoint agonist antibodies for autoimmune and inflammatory disorders that can be used to apply the “natural brakes” of the immune system. 7 integrin, with three candidates in early-stage clinical development.

Immunization 104

Immunization 104

Pharmaceutical Technology

JUNE 30, 2023

Cold agglutinin diseaseis under clinical development by NovelMed Therapeutics and currently in Phase I for Acquired (Autoimmune) Hemolytic Anemia.

52

52

European Pharmaceutical Review

FEBRUARY 24, 2023

The researchers noted that risk of developing a very severe form of the autoimmune inflammatory disease is high. This is the second type of autoimmune disease that physicians and researchers at the Deutsches Zentrum Immuntherapie (DZI) at Universitätsklinikum Erlangen have successfully treated using CAR T-cell therapy.

Immunization 128

Immunization Hospitals 128

The Thyroid Pharmacist

AUGUST 12, 2022

Did you know that most cases of thyroid disease are autoimmune in nature? (1). Hashimoto’s thyroiditis is an autoimmune condition that happens to affect the thyroid gland. It takes an average of 10 years to be diagnosed with Hashimoto’s between the start of the autoimmune attack on the thyroid gland, and when the person is diagnosed.

Immunization 122

Immunization Adverse Reactions Insurance 122

STAT

DECEMBER 11, 2022

NEW ORLEANS — An antibody treatment developed by the Belgian drugmaker Argenx raised platelet counts and stopped bleeding episodes in patients with a rare autoimmune disorder that causes the body to attack and destroy its own blood-clotting platelets.

Immunization 98

Immunization 98

Pharmaceutical Technology

NOVEMBER 17, 2022

Horizon Therapeutics and Johns Hopkins University School of Medicine have entered a multi-year scientific partnership for advancing autoimmunity and inflammation research. The collaboration will work on identifying new disease targets and developing therapies to treat serious autoimmune and inflammatory conditions.

52

52

Pharmaceutical Technology

JANUARY 4, 2024

Riliprubart is under clinical development by Sanofi and currently in Phase II for Acquired (Autoimmune) Hemolytic Anemia.

40

40

STAT

MARCH 18, 2023

The drug, which it acquired from Boston biotech Nimbus Therapeutics last month, blocks a key lever in the immune system that Takeda believes has the potential to treat numerous autoimmune and inflammatory diseases.

Immunization 106

Immunization 106

Pharmaceutical Technology

NOVEMBER 18, 2023

Rilzabrutinib is under clinical development by Principia Biopharma and currently in Phase II for Acquired (Autoimmune) Hemolytic Anemia.

40

40

STAT

FEBRUARY 17, 2023

SAN DIEGO — Travere Therapeutics, a biotech focused both on treating rare diseases and distancing itself from controversial founder Martin Shkreli, on Friday won accelerated approval for a drug that treats IgA nephropathy, a rare and deadly autoimmune disease that attacks the kidneys and can lead to organ failure.

FDA 100

FDA 100

Pharmaceutical Technology

APRIL 20, 2023

The funds will support Maxion’s KnotBody platform to develop antibodies to treat autoimmune diseases. Antibody-based therapies provide enhanced efficacy and safety whilst reducing the need for frequent administration for autoimmune disease treatment. As per Maxion, there are more than 80 types of autoimmune conditions.

52

52

Pharmaceutical Technology

MAY 15, 2023

Biotech company Dualyx, based in Ghent, Belgium, has raised $43.39m (€40m) in a Series A financing round to progress Treg therapies [therapies using regulatory T cells] to treat autoimmune diseases into clinical trials. DT-001 is currently involved in investigational new drug (IND)-enabling studies.

Immunization 52

Immunization 52

European Pharmaceutical Review

JANUARY 4, 2023

The companies will collaborate to advance preclinical development and Gilead will be responsible for clinical development and commercialisation. The technology has the potential to change the paradigm for the treatment of autoimmune diseases.

Immunization 99

Immunization 99

Hospital Pharmacy Europe

FEBRUARY 18, 2023

Having one of several autoimmune diseases have been found to increase the risk of developing new-onset atrial fibrillation over time Patients with autoimmune diseases (AIDs) are at an elevated risk of subsequently developing atrial fibrillation according to the findings of a prospective study by Dutch researchers.

Hospitals 52

Hospitals 52

Outsourcing Pharma

APRIL 13, 2021

The two companies have partnered to develop a systemic erythematosus assessment review to streamline clinical trials centered on the autoimmune disease.

80

80

Pharmafile

APRIL 4, 2023

InnoCare has announced that the first subject has been dosed in its clinical trial of its novel targeted protein degrader ICP-490 in China. The company focuses on the treatment of cancer and autoimmune diseases, with this candidate aiming to treat multiple myeloma (MM) and non-Hodgkin’s lymphoma (NHL). read more

Communication 52

Communication 52

Outsourcing Pharma

SEPTEMBER 19, 2022

Autoimmune diagnostics life sciences company Exagen is heralding the completion of the CAPSTONE study as evidence that its AVISE Lupus test is more clinically effective than traditional ANA methods (tANA), benefiting patients, providers and payers by enabling decisive clinical action and early treatment.

52

52

pharmaphorum

SEPTEMBER 30, 2022

Almirall has licensed an interleukin-2 (IL-2) drug from China’s Simcere Pharma, joining the ranks of companies looking at blocking the cytokine as a way to treat autoimmune diseases. The post Almirall joins IL-2 push in autoimmunity with $507m Simcere deal appeared first on. Last year, Merck & Co paid $1.85

Immunization 52

Immunization 52

European Pharmaceutical Review

APRIL 17, 2023

Its chosen indications are ulcerative colitis (UC) and Crohn’s disease (CD) and other autoimmune conditions. Prometheus is a clinical-stage biotechnology company. “I The agreement is set to help advance PRA023, a novel humanised monoclonal antibody (mAb), developed by Prometheus.

Research Laboratories 96

Research Laboratories Immunization 96

pharmaphorum

JULY 1, 2022

billion buyout of Principia Biopharma has run into trouble, after the FDA placed it on partial clinical hold while a safety signal is investigated. All the BTK inhibitors are designed to be able to cross the blood brain barrier and enter the central nervous system, dampening down the autoimmune response that leads to neuronal damage in MS.

FDA 98

FDA 98

pharmaphorum

MAY 17, 2022

AbbVie and Cugene have teamed up to research autoimmune diseases and cancer in an exclusive worldwide agreement. The Chicago-based pharma firm, AbbVie, received the option to license worldwide rights to Cugene’s CUG252 – a clinical-stage and potential best-in-class Treg-selective IL-2 mutein. AbbVie’s Rinvoq made $1.65

Immunization 58

Immunization 58

Pharmaceutical Technology

DECEMBER 7, 2022

AbbVie has entered an exclusive global partnership and option to licence agreement for HotSpot Therapeutics’ interferon regulatory factor 5 (IRF5) programme, which is in the discovery stage, to treat autoimmune diseases. HotSpot focuses on discovering and developing small-molecule allosteric therapies for cancer and autoimmune ailments.

59

59